Unexplained weight loss (UWL), defined as a decrease in body weight of 5% or more within a six-month period without a clear cause, is a common yet challenging clinical scenario. It may be an indicator of underlying serious conditions, both malignant and non-malignant, warranting a comprehensive evaluation.
The initial approach to evaluating UWL should include a detailed history and physical examination. The history should focus on dietary intake, physical activity, changes in taste or smell, psychiatric symptoms, and other systemic symptoms. The physical examination should aim at identifying signs of chronic diseases, malignancies, or malnutrition.
Initial laboratory tests should include complete blood count, metabolic panel, thyroid function tests, and inflammatory markers. The role of imaging studies is not well-defined in the absence of specific symptoms or signs, but computed tomography (CT) of the abdomen and pelvis may be considered in certain cases.
Special populations may require additional investigations. In the elderly, cognitive impairment and social factors may contribute to UWL. In patients with HIV, UWL may be a sign of uncontrolled disease or opportunistic infections. In these cases, a tailored approach may be necessary.
Management should be directed at the underlying cause, if identified. In cases where no clear cause is found, symptomatic and nutritional support should be provided. A close follow-up is essential to monitor for new symptoms or signs that may point to a specific diagnosis.
Unexplained weight loss is a complex clinical issue that requires a systematic and comprehensive approach. While it can be a sign of serious underlying conditions, a thorough evaluation often leads to the identification of treatable causes. Continued research into this area is needed to further refine our approach and improve patient outcomes.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation